JoyceAnnO'ShaughnessyMD

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. O'Shaughnessy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Shaughnessy's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1809

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Massachusetts General HospitalResidency, Internal Medicine, 1982 - 1985
Yale School of MedicineClass of 1982

Certifications & Licensure

TX State Medical License 1997 - 2026
IN State Medical License 1995 - 1999
KY State Medical License 1995 - 1999
MD State Medical License 1985 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

PhII ICb With/Without Erbitux in MBC Pts Start of enrollment: 2005 Jul 28
Active, not recruiting
Phase 2
Satraplatin for Patients With Metastatic Breast Cancer (MBC) Start of enrollment: 2005 Nov 01
Completed
Phase 2
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Triple Negative Breast Cancer Biomarker Study Start of enrollment: 2010 May 01
Completed
Tesetaxel as First-line Therapy for Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Unknown status
Phase 2
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients Start of enrollment: 2012 Dec 01
Completed
Phase 1
STAR Cape+BKM120 MBC With Brain Met Start of enrollment: 2014 May 29
Completed
Phase 2
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Start of enrollment: 2015 Feb 12
Active, not recruiting
Phase 2
Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue Start of enrollment: 2016 Jan 01
Terminated
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Start of enrollment: 2017 Nov 29
Active, not recruiting
Phase 1, Phase 2
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer Start of enrollment: 2018 Feb 08
Completed
Not Applicable
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer Start of enrollment: 2019 Sep 05
Completed
Phase 2
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC Start of enrollment: 2020 Oct 15
Recruiting
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

218 citations
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
N. Harbeck, Priya Rastogi, M. Martin, Sara M. Tolaney, Z-M Shao
Annals of Oncology. 2021-09-29
476 citations
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff
The New England Journal of Medicine. 2019-02-20
516 citations
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat
Annals of Oncology. 2019-03-01

Lectures

CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone...
2019 ASCO Annual Meeting - 6/1/2019
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 lo...
2019 ASCO Annual Meeting - 6/1/2019
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

What Is Inflammatory Breast Cancer? Patient Jennifer Cordts Talks with Dr. Joyce O’ShaughnessyFebruary 28th, 2023
Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCSJanuary 24th, 2023
Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast CancerOctober 20th, 2021
Join now to see all

JoyceAnnO'ShaughnessyMD

Dr. O'Shaughnessy is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.